Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EPS (Weighted Average and Diluted) (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of EPS (Weighted Average and Diluted) readings, the most recent being $1.48 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 48.0% to $1.48 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.66, a 41.64% increase, with the full-year FY2025 number at $4.67, up 41.95% from a year prior.
  • EPS (Weighted Average and Diluted) hit $1.48 in Q4 2025 for Neurocrine Biosciences, down from $2.04 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.04 in Q3 2025 to a low of -$0.79 in Q1 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.66 (2024), compared with a mean of $0.64.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1371.43% in 2022 and later tumbled 664.29% in 2023.
  • Neurocrine Biosciences' EPS (Weighted Average and Diluted) stood at -$0.07 in 2021, then surged by 1371.43% to $0.89 in 2022, then skyrocketed by 64.04% to $1.46 in 2023, then tumbled by 31.51% to $1.0 in 2024, then skyrocketed by 48.0% to $1.48 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $1.48 (Q4 2025), $2.04 (Q3 2025), and $1.06 (Q2 2025) per Business Quant data.